Literature DB >> 22998469

Inborn errors of metabolism causing epilepsy.

Shamima Rahman1, Emma J Footitt, Sophia Varadkar, Peter T Clayton.   

Abstract

Seizures may be the first and the major presenting feature of an inborn error of metabolism (IEM), for example in a neonate with pyridoxine-dependent epilepsy. In other IEMs, seizures may be preceded by other major symptoms: by a reduced level of consciousness in a child with an organic acidaemia or urea cycle defect; or by loss of skills, progressive weakness, ataxia, and upper motor signs in a child with a lysosomal storage disorder or peroxisomal leukodystrophy. This review concentrates on those IEMs for which specific treatment is available. The common metabolic causes of seizures vary according to the age at presentation. Features from the history, examination, imaging, and first line biochemical investigations can all provide clues to an inborn error. This review attempts to delineate these and to provide a guide to the specific tests that can be used to make the diagnosis of disorders with specific treatment. © The Authors. Developmental Medicine & Child Neurology
© 2012 Mac Keith Press.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22998469     DOI: 10.1111/j.1469-8749.2012.04406.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  17 in total

1.  Diagnosis of glycine encephalopathy in a pediatric patient by detection of a GLDC mutation during initial next generation DNA sequencing.

Authors:  Fatih Ezgu; Bahattin Çiftci; Burcu Topçu; Gülcan Adıyaman; Hatice Gökmenoğlu; Aynur Küçükçongar; Çiğdem Kasapkara; Gürsel Biberoğlu; Leyla Tümer; Alev Hasanoğlu
Journal:  Metab Brain Dis       Date:  2014-01-11       Impact factor: 3.584

2.  A preterm neonate with seizures unresponsive to conventional treatment.

Authors:  Francesco Raimondi; Philippa Mills; Peter T Clayton; Ennio Del Giudice
Journal:  BMJ Case Rep       Date:  2015-05-14

3.  Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade.

Authors:  Gregg W Crabtree; Alan J Park; Joshua A Gordon; Joseph A Gogos
Journal:  Cell Rep       Date:  2016-10-04       Impact factor: 9.423

Review 4.  An Introduction to Pharmacotherapy for Inborn Errors of Metabolism.

Authors:  Aaron A Harthan
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Nov-Dec

Review 5.  [Epilepsy-new diagnostic tools, old drugs? : Therapeutic consequences of epilepsy genetics].

Authors:  M Tacke; B A Neubauer; L Gerstl; T Roser; J Rémi; I Borggraefe
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

Review 6.  Inborn Errors of Metabolism in Pediatric Epilepsy.

Authors:  Anna S Cosnahan; Christopher T Campbell
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Sep-Oct

Review 7.  Neonatal seizures: advances in mechanisms and management.

Authors:  Hannah C Glass
Journal:  Clin Perinatol       Date:  2013-12-12       Impact factor: 3.430

Review 8.  Contemporary scope of inborn errors of metabolism involving epilepsy or seizures.

Authors:  Birutė Tumienė; Borut Peterlin; Aleš Maver; Algirdas Utkus
Journal:  Metab Brain Dis       Date:  2018-07-13       Impact factor: 3.584

Review 9.  Epileptic Encephalopathy in Childhood: A Stepwise Approach for Identification of Underlying Genetic Causes.

Authors:  Jaina Patel; Saadet Mercimek-Mahmutoglu
Journal:  Indian J Pediatr       Date:  2016-01-29       Impact factor: 1.967

10.  Clinico-radiological features, molecular spectrum, and identification of prognostic factors in developmental and epileptic encephalopathy due to inosine triphosphate pyrophosphatase (ITPase) deficiency.

Authors:  Marcello Scala; Saskia B Wortmann; Namik Kaya; Menno D Stellingwerff; Angela Pistorio; Emma Glamuzina; Clara D van Karnebeek; Cristina Skrypnyk; Katarzyna Iwanicka-Pronicka; Dorota Piekutowska-Abramczuk; Elżbieta Ciara; Frederic Tort; Beth Sheidley; Annapurna Poduri; Parul Jayakar; Anuj Jayakar; Jariya Upadia; Nicolette Walano; Tobias B Haack; Holger Prokisch; Hesham Aldhalaan; Ehsan G Karimiani; Yilmaz Yildiz; Ahmet C Ceylan; Teresa Santiago-Sim; Amy Dameron; Hui Yang; Mehran B Toosi; Farah Ashrafzadeh; Javad Akhondian; Shima Imannezhad; Hanieh S Mirzadeh; Shazia Maqbool; Aisha Farid; Mohamed A Al-Muhaizea; Meznah O Alshwameen; Lama Aldowsari; Maysoon Alsagob; Ashwaq Alyousef; Rawan AlMass; Aljouhra AlHargan; Ali H Alwadei; Maha M AlRasheed; Dilek Colak; Hanan Alqudairy; Sameena Khan; Matthew A Lines; M Ángeles García Cazorla; Antonia Ribes; Eva Morava; Farah Bibi; Shahzad Haider; Matteo P Ferla; Jenny C Taylor; Hessa S Alsaif; Abdulwahab Firdous; Mais Hashem; Chingiz Shashkin; Kairgali Koneev; Rauan Kaiyrzhanov; Stephanie Efthymiou; Queen Square Genomics; Thomas Schmitt-Mechelke; Andreas Ziegler; Mahmoud Y Issa; Hasnaa M Elbendary; Pasquale Striano; Fowzan S Alkuraya; Maha S Zaki; Joseph G Gleeson; Tahsin Stefan Barakat; Jorgen Bierau; Marjo S van der Knaap; Reza Maroofian; Henry Houlden
Journal:  Hum Mutat       Date:  2022-01-12       Impact factor: 4.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.